Kathleen R Lamborn

Summary

Affiliation: University of California
Country: USA

Publications

  1. pmc Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis
    Kathleen R Lamborn
    Department of Neurological Surgery, University of California San Francisco, San Francisco, CA 94143 0112, USA
    Neuro Oncol 6:227-35. 2004
  2. pmc Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas
    Kathleen R Lamborn
    Department of Neurological Surgery, University of California San Francisco, 400 Parnassus Avenue, UC Clinics 808, San Francisco, CA 94143 0372, USA
    Neuro Oncol 10:162-70. 2008
  3. pmc Tumor regrowth between surgery and initiation of adjuvant therapy in patients with newly diagnosed glioblastoma
    Andrea Pirzkall
    Department of Radiology and Margaret Hart Surbeck Laboratory of Advanced Imaging, University of California, San Francisco, San Francisco, CA, USA
    Neuro Oncol 11:842-52. 2009
  4. pmc Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma
    Nicholas Butowski
    Neuro Oncology Service, Department of Neurological Surgery, University of California, San Francisco, 400 Parnassus Avenue, A808, San Francisco, CA 94143 0350, USA
    Neuro Oncol 13:1331-8. 2011
  5. ncbi request reprint A phase II study of concurrent temozolomide and cis-retinoic acid with radiation for adult patients with newly diagnosed supratentorial glioblastoma
    Nicholas Butowski
    Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA
    Int J Radiat Oncol Biol Phys 61:1454-9. 2005
  6. pmc A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas
    Nicholas Butowski
    Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA 94143 0350, USA
    J Neurooncol 91:183-9. 2009
  7. doi request reprint Neurosurgical management and prognosis of patients with glioblastoma that progresses during bevacizumab treatment
    Aaron J Clark
    Department of Neurological Surgery, University of California, San Francisco, San Francisco, California 94143 0112, USA
    Neurosurgery 70:361-70. 2012
  8. pmc Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy
    Suja Saraswathy
    Department of Radiology and Biomedical Imaging, UCSF, Box 2532, Byers Hall, 1700 4th Street, San Francisco, CA, 94143 2532, USA
    J Neurooncol 91:69-81. 2009
  9. pmc Permanent iodine 125 brachytherapy in patients with progressive or recurrent glioblastoma multiforme
    David A Larson
    Department of Radiation Oncology, University of California San Francisco, San Francisco, CA 94143, USA
    Neuro Oncol 6:119-26. 2004
  10. doi request reprint Preoperative prognostic classification system for hemispheric low-grade gliomas in adults
    Edward F Chang
    Brain Tumor Research Center, Department of Neurological Surgery, University of California, San Francisco, California 94143, USA
    J Neurosurg 109:817-24. 2008

Detail Information

Publications90

  1. pmc Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis
    Kathleen R Lamborn
    Department of Neurological Surgery, University of California San Francisco, San Francisco, CA 94143 0112, USA
    Neuro Oncol 6:227-35. 2004
    ....
  2. pmc Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas
    Kathleen R Lamborn
    Department of Neurological Surgery, University of California San Francisco, 400 Parnassus Avenue, UC Clinics 808, San Francisco, CA 94143 0372, USA
    Neuro Oncol 10:162-70. 2008
    ..Earlier assessments of progression status also predicted survival and may be incorporated in the design of future clinical trials...
  3. pmc Tumor regrowth between surgery and initiation of adjuvant therapy in patients with newly diagnosed glioblastoma
    Andrea Pirzkall
    Department of Radiology and Margaret Hart Surbeck Laboratory of Advanced Imaging, University of California, San Francisco, San Francisco, CA, USA
    Neuro Oncol 11:842-52. 2009
    ..The acquisition of metabolic and physiologic imaging data prior to adjuvant therapy may also be valuable in assessing regions of new CE and nonenhancing tumor...
  4. pmc Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma
    Nicholas Butowski
    Neuro Oncology Service, Department of Neurological Surgery, University of California, San Francisco, 400 Parnassus Avenue, A808, San Francisco, CA 94143 0350, USA
    Neuro Oncol 13:1331-8. 2011
    ..Adjusting for age and KPS, no other biomarker was associated with survival outcome. Correlation of relevant biomarkers with OS may be useful in future trials...
  5. ncbi request reprint A phase II study of concurrent temozolomide and cis-retinoic acid with radiation for adult patients with newly diagnosed supratentorial glioblastoma
    Nicholas Butowski
    Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA
    Int J Radiat Oncol Biol Phys 61:1454-9. 2005
    ....
  6. pmc A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas
    Nicholas Butowski
    Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA 94143 0350, USA
    J Neurooncol 91:183-9. 2009
    ..Based on this study, poly-ICLC does not improve 6moPFS in patients with recurrent anaplastic gliomas but may be worth further study in combination with agents such as temozolomide...
  7. doi request reprint Neurosurgical management and prognosis of patients with glioblastoma that progresses during bevacizumab treatment
    Aaron J Clark
    Department of Neurological Surgery, University of California, San Francisco, San Francisco, California 94143 0112, USA
    Neurosurgery 70:361-70. 2012
    ..The management and prognosis of glioblastoma patients after Stupp protocol treatment and progression during bevacizumab (BV) treatment remain undefined...
  8. pmc Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy
    Suja Saraswathy
    Department of Radiology and Biomedical Imaging, UCSF, Box 2532, Byers Hall, 1700 4th Street, San Francisco, CA, 94143 2532, USA
    J Neurooncol 91:69-81. 2009
    ..This information may be important for stratifying patients to specific treatment protocols and for planning focal therapy...
  9. pmc Permanent iodine 125 brachytherapy in patients with progressive or recurrent glioblastoma multiforme
    David A Larson
    Department of Radiation Oncology, University of California San Francisco, San Francisco, CA 94143, USA
    Neuro Oncol 6:119-26. 2004
    ..We conclude that permanent 125I brachytherapy for recurrent or progressive GM is well tolerated. Survival time was comparable to that of a similar group of patients treated with temporary brachytherapy...
  10. doi request reprint Preoperative prognostic classification system for hemispheric low-grade gliomas in adults
    Edward F Chang
    Brain Tumor Research Center, Department of Neurological Surgery, University of California, San Francisco, California 94143, USA
    J Neurosurg 109:817-24. 2008
    ..As a result, the objective in the present study was to design a preoperative scoring system to prognosticate long-term outcomes in patients with LGGs...
  11. pmc Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma
    Michael D Prados
    Department of Neurosurgery, University of California, San Francisco, CA 94143 0372, USA
    Neuro Oncol 8:67-78. 2006
    ..There was a modest pharmacokinetic interaction between erlotinib and temozolomide. The favorable tolerability profile and evidence of antitumor activity indicate that further investigation of erlotinib is warranted...
  12. pmc Relationship of pre-surgery metabolic and physiological MR imaging parameters to survival for patients with untreated GBM
    Forrest W Crawford
    Department of Radiology, University of California San Francisco, 1700 4th Street, San Francisco, CA 94143 2532, USA
    J Neurooncol 91:337-51. 2009
    ..These parameters may provide useful information for predicting outcome and for the stratification of patients into high or low risk groups for clinical trials...
  13. doi request reprint Radiation is an important component of multimodality therapy for pediatric non-pineal supratentorial primitive neuroectodermal tumors
    Sean M McBride
    Department of Radiation Oncology, University of California San Francisco, San Francisco, CA
    Int J Radiat Oncol Biol Phys 72:1319-23. 2008
    ..To review a historical cohort of pediatric patients with supratentorial primitive neuroectodermal tumors (sPNET), to clarify the role of radiation in the treatment of these tumors...
  14. pmc Quality of life in low-grade glioma patients receiving temozolomide
    Raymond Liu
    Department of Medicine, Division of Hematology Oncology Neuro Oncology, University of California, San Francisco, CA 94143 2167, USA
    Neuro Oncol 11:59-68. 2009
    ..While remaining on therapy, LGG patients were able to maintain their QOL in all realms. LGG patients' QOL may be further improved by addressing their emotional well-being and their loss of independence in terms of driving or working...
  15. ncbi request reprint Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib
    Daphne A Haas-Kogan
    Department of Neurosurgery, Brain Tumor Research Center, University of California San Francisco, 1600 Divisadero Street, Suite H1031, San Francisco, CA 94143, USA
    J Natl Cancer Inst 97:880-7. 2005
    ....
  16. pmc New therapeutic approach for brain tumors: Intranasal delivery of telomerase inhibitor GRN163
    Rintaro Hashizume
    Brain Tumor Research Center, Department of Neurological Surgery, University of California San Francisco, San Francisco, CA 94143 0520, USA
    Neuro Oncol 10:112-20. 2008
    ..These data support further development of intranasal delivery of tumor-specific therapeutic agents for brain tumor patients...
  17. ncbi request reprint Cytosine deaminase/5-fluorocytosine exposure induces bystander and radiosensitization effects in hypoxic glioblastoma cells in vitro
    Jennifer K Chen
    Brain Tumor Research Center of the Department of Neurological Surgery, University of California San Francisco, San Francisco, CA 94143, USA
    Int J Radiat Oncol Biol Phys 67:1538-47. 2007
    ..In this study, we investigated whether cytosine deaminase (CD)/5-fluorocytosine (5-FC) enzyme/prodrug treatment induced a bystander effect (BE) and/or radiosensitization in hypoxic GBM cells...
  18. ncbi request reprint Phase I trial of gross total resection, permanent iodine-125 brachytherapy, and hyperfractionated radiotherapy for newly diagnosed glioblastoma multiforme
    Allen M Chen
    Department of Radiation Oncology, University of California, San Francisco School of Medicine, San Francisco, CA 94143 0226, USA
    Int J Radiat Oncol Biol Phys 69:825-30. 2007
    ..To evaluate the feasibility of gross total resection and permanent I-125 brachytherapy followed by hyperfractionated radiotherapy for patients with newly diagnosed glioblastoma...
  19. ncbi request reprint Functionality of hypoxia-induced BAX expression in a human glioblastoma xenograft model
    Tomoko Ozawa
    Brain Tumor Research Center, Department of Neurological Surgery, University of California San Francisco, San Francisco, CA 94143 0520, USA
    Cancer Gene Ther 12:449-55. 2005
    ..These results suggest that the tumor microenvironment is sufficiently hypoxic to trigger HRE-mediated cell killing via the BAX apoptotic pathway...
  20. doi request reprint Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas
    Justin S Smith
    Department of Neurological Surgery, Brain Tumor Research Center, University of California San Francisco, 505 Parnassus Ave, Room M 779, San Francisco, CA 94143 0112, USA
    J Clin Oncol 26:1338-45. 2008
    ..The prognostic role of extent of resection (EOR) of low-grade gliomas (LGGs) is a major controversy. We designed a retrospective study to assess the influence of EOR on long-term outcomes of LGGs...
  21. doi request reprint Seizure characteristics and control following resection in 332 patients with low-grade gliomas
    Edward F Chang
    Department of Neurological Surgery and Brain Tumor Research Center, University of California, San Francisco, California 94143, USA
    J Neurosurg 108:227-35. 2008
    ..The aim of this study was to identify factors that influenced perioperative seizure characteristics and postoperative seizure control...
  22. ncbi request reprint Toxicity, biodistribution, and convection-enhanced delivery of the boronated porphyrin BOPP in the 9L intracerebral rat glioma model
    Tomoko Ozawa
    Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA 94143 0446, USA
    Int J Radiat Oncol Biol Phys 63:247-52. 2005
    ..To investigate the toxicity, biodistribution, and convection-enhanced delivery (CED) of a boronated porphyrin (BOPP) that was designed for boron neutron capture therapy and photodynamic therapy...
  23. ncbi request reprint Historical controls for phase II surgically based trials requiring gross total resection of glioblastoma multiforme
    Nicholas Butowski
    Neuro Oncology Service, Department of Neurological Surgery, University of California, San Francisco, 400 Parnassus Avenue, A808, San Francisco, CA 94143 0350, USA
    J Neurooncol 85:87-94. 2007
    ..Patients treated during surgically based phase II studies should be matched with a historical control group restricted to patients with similar pretreatment variables, including GTR...
  24. pmc The role of up-front radiation therapy for incompletely resected pediatric WHO grade II low-grade gliomas
    Kavita K Mishra
    Brain Tumor Research Center and Department of Radiation Oncology, University of California, San Francisco, San Francisco, CA 94143, USA
    Neuro Oncol 8:166-74. 2006
    ..We were unable to demonstrate a benefit for administering radiation as part of initial treatment. An outcome benefit was seen with greater extent of resection...
  25. ncbi request reprint Chromosome transfer experiments link regions on chromosome 7 to radiation resistance in human glioblastoma multiforme
    Anjan Misra
    Brain Tumor Research Center, Department of Neurosurgery, University of California San Francisco, San Francisco, CA 94143 0808, USA
    Genes Chromosomes Cancer 45:20-30. 2006
    ..We identified three candidate regions on chromosome 7 that conferred radiation resistance in our model system...
  26. pmc Signal transduction molecules in gliomas of all grades
    Ralph P Ermoian
    Department of Radiation Oncology, The University of California, San Francisco, 1600 Divisadero St Suite H1031, San Francisco, CA, 94143 1708, USA
    J Neurooncol 91:19-26. 2009
    ..To address the multiple comparisons, first an overall analysis was done comparing the four groups using Spearman's Correlation Coefficient. Only if this analysis was statistically significant were individual pairwise comparisons done...
  27. pmc Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma
    Michael D Prados
    University of California, San Francisco, CA 94143, USA
    J Clin Oncol 27:579-84. 2009
    ..The objectives were to determine efficacy of this treatment as measured by survival and to explore the relationship between molecular markers and treatment response...
  28. pmc Antitumor effects of specific telomerase inhibitor GRN163 in human glioblastoma xenografts
    Tomoko Ozawa
    Brain Tumor Research Center of the Department of Neurological Surgery, University of California San Francisco, San Francisco, CA 94143 0520, USA
    Neuro Oncol 6:218-26. 2004
    ..These findings support further development of this compound as a potential anticancer agent...
  29. pmc Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma?
    Jennifer L Clarke
    Department of Neurological Surgery, University of California, San Francisco, 400 Parnassus Avenue, A 808, San Francisco, CA 94143 0372, USA
    Neuro Oncol 13:1118-24. 2011
    ....
  30. ncbi request reprint Genetic aberrations defined by comparative genomic hybridization distinguish long-term from typical survivors of glioblastoma
    Eric C Burton
    Department of Neurological Surgery, University of California, San Francisco 94143, USA
    Cancer Res 62:6205-10. 2002
    ..Loss of 19q may be a marker of long-term survival...
  31. pmc High failure rate in spinal ependymomas with long-term follow-up
    Daniel R Gomez
    Department of Radiation Oncology, University of California, San Francisco, CA 94143, USA
    Neuro Oncol 7:254-9. 2005
    ..The overall high rate of recurrence leads us to recommend radiation to doses of 45 to 54 Gy for all patients who do not have gross total resections, and long, close follow-up...
  32. pmc Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma
    John K Wiencke
    Department of Neurological Surgery and Brain Tumor Research Center, University of California, San Francisco, San Francisco, CA 94143, USA
    Neuro Oncol 9:271-9. 2007
    ....
  33. doi request reprint Long-term recurrence and mortality after surgery and adjuvant radiotherapy for nonfunctional pituitary adenomas
    Edward F Chang
    Department of Neurological Surgery, Division of Endocrinology, University of California, San Francisco, California 94143, USA
    J Neurosurg 108:736-45. 2008
    ..The authors' aim was to determine predictors of recurrence and overall survival and to define patient subgroups that may benefit from radiotherapy...
  34. ncbi request reprint Volumetric extent of resection and residual contrast enhancement on initial surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma
    G Evren Keles
    Department of Neurological Surgery, University of California, San Francisco, California 94143 0112, USA
    J Neurosurg 105:34-40. 2006
    ....
  35. ncbi request reprint Response of intracerebral human glioblastoma xenografts to multifraction radiation exposures
    Tomoko Ozawa
    Brain Tumor Research Center, Department of Neurological Surgery, University of California San Francisco, San Francisco, CA 94143, USA
    Int J Radiat Oncol Biol Phys 66:263-70. 2006
    ..We investigated the effects of fractionated radiation treatments on the life spans of athymic rats bearing intracerebral brain tumors...
  36. pmc Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I study
    Nicholas Butowski
    Department of Neurological Surgery, University of California San Francisco, 400 Parnassus Avenue, A808, San Francisco, CA 94143 0350, USA
    Neuro Oncol 12:608-13. 2010
    ..The proceeding phase II trial has finished accrual and results will be reported in 2009...
  37. ncbi request reprint Bromophenol blue staining of tumors in a rat glioma model
    Tomoko Ozawa
    Department of Neurological Surgery, Brain Tumor Research Center, University of California, San Francisco, California, USA
    Neurosurgery 57:1041-7; discussion 1041-7. 2005
    ..Injection of bromophenol blue (BPB) may enhance intraoperative visualization of an infiltrating tumor and its margins and improve the extent of resection. In this study, we investigated the uptake of BPB in experimental rat brain tumors...
  38. ncbi request reprint Hypoxia-induced BAX overexpression and radiation killing of hypoxic glioblastoma cells
    Jennifer K Chen
    Brain Tumor Research Center, Department of Neurological Surgery, University of California, San Francisco, California 94143 0520, USA
    Radiat Res 163:644-53. 2005
    ..Therefore, we conclude that whether Bax is a radiation enhancer under hypoxia not only is cell line-dependent but also depends on when the Bax overexpression occurs...
  39. ncbi request reprint Treatment for posterior fossa dissemination of primary supratentorial glioma
    Justin S Smith
    Department of Neurological Surgery, Brain Tumor Research Center, University of California, San Francisco, California 94143 0350, USA
    J Neurosurg 106:567-74. 2007
    ..This study was designed to assess the presentation, management, and outcome of cases involving patients who had a supratentorial glioma that subsequently progressed in the posterior fossa (PF)...
  40. ncbi request reprint Biomarkers to predict response to epidermal growth factor receptor inhibitors
    Daphne A Haas-Kogan
    Department of Radiation Oncology, University of California San Francisco, USA
    Cell Cycle 4:1369-72. 2005
    ..Ultimately the goal of these studies is to allow selection of patients who will preferentially respond to EGFR inhibitors...
  41. pmc Apparent diffusion coefficient and fractional anisotropy of newly diagnosed grade II gliomas
    Inas S Khayal
    UCSF UCB Joint Graduate Group in Bioengineering, University of California, San Francisco, CA, USA
    NMR Biomed 22:449-55. 2009
    ..This suggests that ADC and FA may be helpful in directing tissue sampling to the most appropriate regions for taking biopsies in order to make a definitive diagnosis...
  42. ncbi request reprint Prognostic significance of intracranial dissemination of glioblastoma multiforme in adults
    Andrew T Parsa
    Department of Neurological Surgery, School of Medicine, University of California at San Francisco, California 94143, USA
    J Neurosurg 102:622-8. 2005
    ..The objective in the present study was to assess the prognostic significance of disseminated intracranial GBM in adults at presentation and at the time of tumor progression...
  43. doi request reprint A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05)
    Nicholas Butowski
    Department of Neurological Surgery, University of California San Francisco, San Francisco, CA 94143 0350, USA
    J Neurooncol 91:175-82. 2009
    ....
  44. pmc Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide
    Mei Yin C Polley
    Brain Tumor Research Center, Department of Neurological Surgery, University of California San Francisco, 400 Parnassus Avenue, Room A 808, Box 0372, San Francisco, California 94143 2167, USA
    Neuro Oncol 12:274-82. 2010
    ..Our analysis suggests that 6-month PFS may be an appropriate primary endpoint in the context of phase II upfront GBM trials in the TMZ era...
  45. ncbi request reprint Intraoperative subcortical stimulation mapping for hemispherical perirolandic gliomas located within or adjacent to the descending motor pathways: evaluation of morbidity and assessment of functional outcome in 294 patients
    G Evren Keles
    Department of Neurological Surgery, University of California, San Francisco, California 94143 0112, USA
    J Neurosurg 100:369-75. 2004
    ..The purpose of this retrospective analysis was to assess the morbidity and functional outcome associated with this method, thus allowing the surgeon to predict the likelihood of causing a temporary or permanent motor deficit...
  46. ncbi request reprint In vivo evaluation of the boronated porphyrin TABP-1 in U-87 MG intracerebral human glioblastoma xenografts
    Tomoko Ozawa
    Department of Neurological Surgery, University of California, San Francisco, California 94143, USA
    Mol Pharm 1:368-74. 2004
    ..5 mg dose. Thus, we may be able to achieve therapeutic BNCT efficacy with minimal systemic toxicity or radiation-induced damage to normal tissue by administering TABP-1 using CED...
  47. pmc Neurooncology clinical trial design for targeted therapies: lessons learned from the North American Brain Tumor Consortium
    Susan M Chang
    Department of Neurological Surgery, University of California San Francisco, San Francisco, CA 94143 0350, USA
    Neuro Oncol 10:631-42. 2008
    ..It would also include a combined phase 0/I pharmacokinetic study to determine the safety and biologically optimal dose of the agent and to verify successful modulation of the target prior to initiating a larger, phase II efficacy study...
  48. pmc Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme
    Yu Liang
    Preuss Laboratory for Molecular Neuro oncology and Department of Neurological Surgery, University of California San Francisco, San Francisco, CA 94143, USA
    Proc Natl Acad Sci U S A 102:5814-9. 2005
    ..Our analyses thus identify and validate a prognostic marker of both biologic and clinical significance and provide a series of putative markers for additional evaluation...
  49. pmc In vivo efficacy of a novel histone deacetylase inhibitor in combination with radiation for the treatment of gliomas
    Michal Entin-Meer
    Department of Radiation Oncology, Neurological Surgery, and Comprehensive Cancer Center, University of California, San Francisco, CA 94143, USA
    Neuro Oncol 9:82-8. 2007
    ..The data suggest that AN-9 in combination with radiation may be an effective therapy for malignant gliomas...
  50. ncbi request reprint Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme
    Susan M Chang
    Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA
    Int J Radiat Oncol Biol Phys 60:353-7. 2004
    ....
  51. ncbi request reprint Synthesis and comparative toxicology of a series of polyhedral borane anion-substituted tetraphenyl porphyrins
    Myoung Seo Koo
    Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, California 94143, USA
    J Med Chem 50:820-7. 2007
    ..We conclude that thrombocytopenia is the dose limiting toxicity for boronated porphyrins in mammals and suggest that these effects may be due to the porphyrin, not the borane or carborane...
  52. doi request reprint The superiority of conservative resection and adjuvant radiation for craniopharyngiomas
    Adam Schoenfeld
    Department of Radiation Oncology, University of California, San Francisco UCSF, San Francisco, CA 94143 1708, USA
    J Neurooncol 108:133-9. 2012
    ..014). In conclusion, for patients with craniopharyngioma, STR + RT may provide superior clinical outcome, achieving better disease control than STR and limiting side effects associated with aggressive surgical resection...
  53. pmc Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy: a randomized phase II pilot study
    Daniel A Lim
    Department of Neurological Surgery, University of California, San Francisco, 94143, USA
    J Neurooncol 93:349-54. 2009
    ..A large-scale, double-blinded, randomized control trial of LEV versus PHT is required to determine seizure control equivalence and better assess differences in SEs...
  54. pmc Radiation-induced reductions in neurogenesis are ameliorated in mice deficient in CuZnSOD or MnSOD
    Kelly Fishman
    Department of Neurological Surgery, University of California at San Francisco, San Francisco, CA 94110 0899, USA
    Free Radic Biol Med 47:1459-67. 2009
    ..Overall, these data suggest that under conditions of SOD deficiency, there is a common pathway dictating how neurogenesis is affected by ionizing irradiation...
  55. doi request reprint Adjuvant enoxaparin therapy may decrease the incidence of postoperative thrombotic events though does not increase the incidence of postoperative intracranial hemorrhage in patients with meningiomas
    Tene A Cage
    School of Medicine, University of California, San Francisco, CA 94143, USA
    J Neurooncol 93:151-6. 2009
    ..Due to study design and power, we were not able to demonstrate DVT/VTE reduction with statistical significance...
  56. pmc Detection of hypoxia in human brain tumor xenografts using a modified comet assay
    Jingli Wang
    Brain Tumor Research Center, Department of Neurological Surgery, University of California, San Francisco, CA 94143, USA
    Neoplasia 5:288-96. 2003
    ..For U251 MG tumors, there was a positive relationship between tumor size and the degree of hypoxia, whereas preliminary data from U87 MG i.c. tumors showed less hypoxia and no apparent relationship between tumor size and hypoxia...
  57. ncbi request reprint Array comparative genomic hybridization identifies genetic subgroups in grade 4 human astrocytoma
    Anjan Misra
    Brain Tumor Research Center, Department of Neurosurgery, University of California San Francisco, San Francisco, California, USA
    Clin Cancer Res 11:2907-18. 2005
    ..The significance of these genetic groups to therapeutics needs further study...
  58. ncbi request reprint Serum IgE, tumor epidermal growth factor receptor expression, and inherited polymorphisms associated with glioma survival
    Margaret Wrensch
    Department of Neurological Surgery, University of California San Francisco, San Francisco, California 94102, USA
    Cancer Res 66:4531-41. 2006
    ..3 region influence survival. We also suggest that tumor EGFR expression be incorporated into clinical evaluation of anaplastic astrocytoma patients...
  59. ncbi request reprint Repeated operations for infiltrative low-grade gliomas without intervening therapy
    Meic H Schmidt
    Department of Neurological Surgery, University of California at San Francisco, California, USA
    J Neurosurg 98:1165-9. 2003
    ..The authors examined factors that may be associated with tumor progression...
  60. ncbi request reprint Phase II study of high central dose Gamma Knife radiosurgery and marimastat in patients with recurrent malignant glioma
    David A Larson
    Department of Radiation Oncology, University of California, San Francisco, School of Medicine, San Francisco, CA 94143 0226, USA
    Int J Radiat Oncol Biol Phys 54:1397-404. 2002
    ..To assess the outcome of high central dose Gamma Knife radiosurgery plus marimastat in patients with recurrent malignant glioma...
  61. pmc Multiparametric characterization of grade 2 glioma subtypes using magnetic resonance spectroscopic, perfusion, and diffusion imaging
    Wei Bian
    Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA
    Transl Oncol 2:271-80. 2009
    ....
  62. ncbi request reprint Volume of residual disease as a predictor of outcome in adult patients with recurrent supratentorial glioblastomas multiforme who are undergoing chemotherapy
    G Evren Keles
    Department of Neurological Surgery, University of California, San Francisco, California 94143 0112, USA
    J Neurosurg 100:41-6. 2004
    ..To accomplish this, the authors evaluated a homogeneous group of patients with recurrent GBMs who received the same chemotherapeutic agent...
  63. ncbi request reprint Changes in transcranial motor evoked potentials during intramedullary spinal cord tumor resection correlate with postoperative motor function
    Alfredo Quinones-Hinojosa
    Department of Neurological Surgery, University of California, San Francisco, San Francisco, California 94143 0112, USA
    Neurosurgery 56:982-93; discussion 982-93. 2005
    ..In this study, we hypothesized that changes in the intraoperative MEPs during tumor resection correlate with postoperative motor function deficits...
  64. ncbi request reprint Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme
    Susan M Chang
    University of California, San Francisco, San Francisco, CA 94143, USA
    Invest New Drugs 23:357-61. 2005
    ..CCI-779 is an inhibitor of mTOR. The primary objectives of this study were to determine the efficacy of CCI-779 in patients with recurrent GBM and to further assess the toxicity of the drug...
  65. pmc Relationship between choline and apparent diffusion coefficient in patients with gliomas
    Inas S Khayal
    University of California, San Francisco, California, USA
    J Magn Reson Imaging 27:718-25. 2008
    ....
  66. ncbi request reprint Incidence of venous thromboembolism in patients undergoing craniotomy and motor mapping for glioma without intraoperative mechanical prophylaxis to the contralateral leg
    Kurtis I Auguste
    Department of Neurological Surgery, Brain Tumor Research Center, University of California, San Francisco School of Medicine, San Francisco, California 94143 0112, USA
    J Neurosurg 99:680-4. 2003
    ....
  67. pmc Prognostic significance of an apoptotic index and apoptosis/proliferation ratio for patients with high-grade astrocytomas
    Hiroko Kuriyama
    The Preuss Laboratory for Molecular Neuro Oncology, Brain Tumor Research Center, University of California San Francisco, San Francisco, CA 94143, USA
    Neuro Oncol 4:179-86. 2002
    ....
  68. ncbi request reprint Radiation therapy for intracranial germ cell tumors
    Daphne A Haas-Kogan
    Department of Radiation Oncology, University of California, San Francisco, CA 94143, USA
    Int J Radiat Oncol Biol Phys 56:511-8. 2003
    ....
  69. ncbi request reprint Predictive model for pain recurrence after posterior fossa surgery for trigeminal neuralgia
    Philip V Theodosopoulos
    Department of Neurological Surgery, The University of California San Francisco, 505 Parnassus St, Room M787, Campus Box 0112, San Francisco, CA 94143 0112, USA
    Arch Neurol 59:1297-302. 2002
    ..Surgical exploration of the posterior fossa is the definitive treatment for trigeminal neuralgia refractory to medication, but predictors of its success in effecting long-term pain relief have not been established...
  70. doi request reprint A multicenter, prospective pilot study of gamma knife radiosurgery for mesial temporal lobe epilepsy: seizure response, adverse events, and verbal memory
    Nicholas M Barbaro
    Department of Neurological Surgery, University of California at San Francisco, 94143, USA
    Ann Neurol 65:167-75. 2009
    ..We report the 3-year outcomes of a multicenter, prospective pilot study of RS...
  71. ncbi request reprint Delayed surgical resection reduces intraoperative blood loss for embolized meningiomas
    Jay Y Chun
    Department of Neurological Surgery, Brain Tumor Research Center, University of California, San Francisco, San Francisco, California 94143 0112, USA
    Neurosurgery 50:1231-5; discussion 1235-7. 2002
    ..We evaluated whether immediate surgical resection (< or =24 h) after embolization or delayed surgical resection (>24 h) was more effective in minimizing intraoperative blood loss...
  72. pmc Diagnostic, treatment, and demographic factors influencing survival in a population-based study of adult glioma patients in the San Francisco Bay Area
    Margaret Wrensch
    Department of Neurological Surgery, University of California, San Francisco, 44 Page Street Suite 503, San Francisco, CA 94102 1215, USA
    Neuro Oncol 8:12-26. 2006
    ..Further consideration of impact of marital status, education, and other social factors in glioma survival may be warranted...
  73. ncbi request reprint Correlation of magnetic resonance spectroscopic and growth characteristics within Grades II and III gliomas
    Tracy R McKnight
    Department of Radiology, University of California, San Francisco 94107, USA
    J Neurosurg 106:660-6. 2007
    ....
  74. ncbi request reprint Coregistration accuracy and detection of brain shift using intraoperative sononavigation during resection of hemispheric tumors
    G Evren Keles
    Department of Neurological Surgery, Brain Tumor Research Center, University of California, San Francisco, San Francisco, California 94143, USA
    Neurosurgery 53:556-62; discussion 562-4. 2003
    ..Sononavigation, which combines real-time anatomic ultrasound data with neuronavigation techniques, is a potentially valuable adjunct during the surgical excision of brain tumors...
  75. ncbi request reprint A design of phase II cancer trials using total and complete response endpoints
    Ying Lu
    Biostatistics Core, UCSF Comprehensive Cancer Center, USA
    Stat Med 24:3155-70. 2005
    ..Our design has the advantage of being close to the traditional Simon two-stage design while still having the flexibility to treat responses (PR and CR in this example) differently than SD...
  76. pmc GNOSIS: guidelines for neuro-oncology: standards for investigational studies-reporting of phase 1 and phase 2 clinical trials
    Susan M Chang
    Department of Neurological Surgery, University of California, San Francisco, CA 94143, USA
    Neuro Oncol 7:425-34. 2005
    ..Our guidelines are summarized in a checklist format that can be used as a framework from which to construct a phase 1 or 2 clinical trial...
  77. ncbi request reprint Gliomatosis cerebri: a review of 22 cases
    G Edward Vates
    Department of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA
    Neurosurgery 53:261-71; discussion 271. 2003
    ..We reviewed data for patients with gliomatosis who were treated at the University of California, San Francisco, during a 10-year period. Our focus was on presentation, radiological and pathological features, and outcomes...
  78. ncbi request reprint Aberrant p53, mdm2, and proliferation differ in glioblastomas from long-term compared with typical survivors
    Eric C Burton
    Department of Pathology, University of California, San Francisco, San Francisco, California 94143, USA
    Clin Cancer Res 8:180-7. 2002
    ..Only 2-5% of patients originally diagnosed with GBM will survive > or = 3 years. Whether tumors from these long-term survivors (LTSs) exhibit molecular genetic differences compared with typical GBM survivors is not known...
  79. ncbi request reprint Dysregulation of PTEN and protein kinase B is associated with glioma histology and patient survival
    Ralph P Ermoian
    Department of Radiation Oncology, The University of California, San Francisco 94143, USA
    Clin Cancer Res 8:1100-6. 2002
    ..This study assessed whether putative effectors of phosphatidylinositol3-kinase, including PTEN, protein kinase B (PKB), and p27(kip1), correlate with each other, with glioma histology, and with patient outcome...
  80. ncbi request reprint Growth of human glioblastomas as xenografts in the brains of athymic rats
    Tomoko Ozawa
    Brain Tumor Research Center, Department of Neurological Surgery, School of Medicine, University of California, San Francisco, California 94143 0520, USA
    In Vivo 16:55-60. 2002
    ..We have developed xenografts of human glioblastoma (GBM) and established the baseline growth parameters and histopathological features of these tumors...
  81. ncbi request reprint VAMP and low-dose, involved-field radiation for children and adolescents with favorable, early-stage Hodgkin's disease: results of a prospective clinical trial
    Sarah S Donaldson
    Stanford University Medical Center, Stanford, CA, USA
    J Clin Oncol 20:3081-7. 2002
    ..To evaluate outcome and assess toxicity of children and adolescents with early-stage, favorable Hodgkin's disease treated with vinblastine, doxorubicin, methotrexate, and prednisone (VAMP) and low-dose, involved-field radiation...
  82. ncbi request reprint Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma
    John G Kuhn
    Pharmacotherapy Education and Research Center, University of Texas Health Science Center, San Antonio, TX 78229 3900, USA
    Clin Cancer Res 13:7401-6. 2007
    ..An additional objective was to determine whether concentrations of temsirolimus or sirolimus were achieved in brain tumor tissue...
  83. ncbi request reprint Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08
    Patrick Y Wen
    Dana Farber Brigham and Women s Cancer Center, Boston, Massachusetts, USA
    Clin Cancer Res 12:4899-907. 2006
    ..Phase II: To determine the therapeutic efficacy of imatinib...
  84. ncbi request reprint Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study
    Timothy F Cloughesy
    UCLA Neuro Oncology Program, David Geffen School of Medicine at UCLA, University of California, Los Angeles, Los Angeles, CA 90095, USA
    J Clin Oncol 24:3651-6. 2006
    ..Because tipifarnib undergoes extensive hepatic metabolism, MTD is doubled in patients on EIAEDs. The population included 67 patients with glioblastoma multiforme (GBM) and an exploratory group of 22 patients with anaplastic glioma (AG)...
  85. ncbi request reprint High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human
    Carol M Richman
    University of California Davis, Sacramento, California 95817, USA
    Clin Cancer Res 11:5920-7. 2005
    ..In these phase I studies, paclitaxel was combined with radioimmunotherapy in patients with metastatic hormone-refractory prostate cancer or advanced breast cancer...
  86. ncbi request reprint Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts
    Patricia A Burke
    University of California at Davis, Sacramento Medical Center, Radiodiagnosis and Therapy Internal Medicine, Sacramento, California 95816, USA
    Cancer Res 62:4263-72. 2002
    ..The enhanced therapeutic synergy is of particular note, having been achieved without additional toxicity...
  87. ncbi request reprint Integrated genomic and epigenomic analyses pinpoint biallelic gene inactivation in tumors
    Giuseppe Zardo
    Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California 94115, USA
    Nat Genet 32:453-8. 2002
    ..Our results show that most aberrant methylation events are focal and independent of deletions, and the rare convergence of these mechanisms can pinpoint biallelic gene inactivation without the use of positional cloning...
  88. ncbi request reprint Transsphenoidal microsurgery for Cushing's disease: initial outcome and long-term results
    Gary D Hammer
    Department of Internal Medicine, Division of Endocrinology and Metabolism, University of Michigan, Ann Arbor, Michigan 48109 0678, USA
    J Clin Endocrinol Metab 89:6348-57. 2004
    ..These results suggest that patients with persistent Cushing's disease require early and aggressive intervention to attempt to prevent this excess mortality...
  89. ncbi request reprint Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts
    Joseph M Tuscano
    Department of Internal Medicine, University of California, Davis Medical Center, Sacramento 95817, USA
    Blood 101:3641-7. 2003
    ..7 was added to RIT. Thus the anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of (90)Y-DOTA-peptide-Lym-1 in lymphoma xenografts without significant toxicity...
  90. ncbi request reprint A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme
    Morris D Groves
    Department of Neuro Oncology, The University of Texas MD Anderson Cancer Center, 1400 Holcombe, 431, Houston, TX, 77030, USA
    J Neurooncol 81:271-7. 2007
    ..Laboratory and clinical data suggest that the anti-angiogenic agent, thalidomide, if combined with cytotoxic agents, may be effective against recurrent glioblastoma multiforme (GBM)...